Xeljanz is a drug that belongs to the Janus kinase (JAK) inhibitor class used to treat a number of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. This medication is an immunosuppressant that works by suppressing the immune system to relieve the patient’s symptoms and inflammation. Xeljanz’s Prescribing Information has essential details that every patient, healthcare provider, and pharmacist should know before prescribing, administering, or dispensing the drug.
One of the primary things to note is that Xeljanz is not recommended for people who have severe liver problems or for those who are allergic to any of its ingredients. This medication also carries a boxed warning for serious infections, malignancies, and thrombosis risks that can lead to death. Therefore, healthcare providers and pharmacists are expected to evaluate the patient’s risk for these events before starting Xeljanz therapy and during treatment.
In addition, Xeljanz has a specific dosage regimen that should be followed for successful treatment outcomes. For example, patients with rheumatoid arthritis or psoriatic arthritis should take Xeljanz 5mg twice daily, while patients with ulcerative colitis are prescribed a higher dose of 10mg twice daily. The dosage should also be adjusted based on the patient’s response to therapy and their individual needs.
Another crucial point in the Xeljanz Prescribing Information is that it interacts with several medications, especially those that affect the CYP3A4 enzyme system. Drugs that are metabolized by the CYP3A4 enzyme, such as ketoconazole and clarithromycin, can increase Xeljanz’s exposure that can lead to adverse effects, while inducers of the CYP3A4 enzyme, such as rifampin, can decrease Xeljanz’s efficacy. Consequently, healthcare providers and pharmacists should evaluate the patient’s concomitant medications and adjust the dosage accordingly.
Lastly, Xeljanz Prescribing Information has important details about the drug’s adverse reactions, including upper respiratory tract infections, diarrhea, and headache. Therefore, patients are advised to report any significant changes or concerns to their healthcare providers promptly.
In summary, Xeljanz Prescribing Information is an essential resource that provides critical details about the drug’s interactions, dosage regimen, contraindications, and adverse reactions. It is imperative that healthcare providers, pharmacists, and patients familiarize themselves with this information for safe and effective treatment outcomes.
